Key Highlights

  • NovoCure (NASDAQ:NVCR) was handed a not approvable letter covering Optune Mya for brain metastases stemming from lung cancer; the agency pointed to unclear clinical benefit and not to safety.
  • A fresh vision-loss caution now applies across every GLP-1 medicine, with Mounjaro and Zepbound from Eli Lilly among them, after a finding of roughly 6 cases per 100,000 patients receiving treatment.
  • Definium disclosed close to USD 1.05 billion in cash and investments, and intends to seek approval for its Phase 3 anxiety medication during the first half of 2027.
  • Together the trio spans a refusal, a labeling change across a whole drug class and a submission timeline, three common routes by which FDA actions move biotech and pharma shares.

1. NovoCure (NASDAQ:NVCR)

On November 9, 2026, the company disclosed that the regulator had returned a not approvable letter regarding its premarket approval request for Optune Mya in non-small cell lung cancer patients with brain spread. Adults who had already received stereotactic radiation for those brain lesions were the intended group, with the device applied afterward to slow further spread within the brain. Doubt centered on how much clinical benefit it offers, not on safety. NovoCure intends to sit down with the FDA to weigh routes that avoid fresh clinical trials, while noting approval is not guaranteed. No share price change was identified for that session. Losing this near-term growth avenue matters less given the glioblastoma Franchise and a Japanese pancreatic cancer approval that keep Revenue flowing. The outcome of that FDA discussion is what to watch.

2. Eli Lilly (NYSE:LLY)

Regulators on November 9 required fresh cautions across the entire GLP-1 category regarding non-arteritic anterior ischemic optic neuropathy, abbreviated NAION, an uncommon eye disorder that may bring abrupt sight loss. Eli Lilly (NYSE:LLY) and Novo Nordisk both sit under this umbrella. Reviewing over 125 trials, the agency counted roughly 6 instances per 100,000 people treated for a year or longer, while placebo or other glucose-lowering treatments produced under 4 per 100,000. Around a dozen products carry the notice, among them Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Rybelsus and the oral product Foundayo. Lilly responded that it will act quickly and noted the notice contains nothing specific to its own products, whereas Novo Nordisk argued the findings do not prove causation. Investors were unfazed, pushing Lilly to USD 1,411.82 that same day. Since the rule covers every company in the class, no single firm gains an advantage, although legal exposure and caution among prescribers merit monitoring.

3. Definium Therapeutics (NASDAQ:DFTX)

Third-quarter figures from Definium Therapeutics (NASDAQ:DFTX) were released November 9, showing approximately USD 241.2 million in cash plus USD 805.7 million in short-term holdings, about USD 1.05 billion together, with a quarterly net loss of USD 51.0 million. Its regulatory route is the story. The lead candidate, DT120 ODT, which is a dissolvable lysergide formulation, succeeded on its primary goal in two Phase 3 trials for generalized anxiety disorder, named Voyage (reported in August) and Panorama (reported September 14, 2026). Within Panorama, the 100 microgram dose lowered anxiety scores by 5.1 points relative to placebo at week 12, a p-value under 0.0001. A pre-submission discussion with the FDA is planned for the fourth quarter of 2026, and filing for approval is expected during the first half of 2027. These trial successes are old news, but the Balance Sheet indicates Definium can finance its way to a filing without raising money right away.

Where Things Stand

These three November 9 FDA developments send mixed signals. NovoCure's not approvable letter takes away a near-term growth path, yet the agency voiced no safety concern and the firm will look for a route that skips new trials. The class-wide GLP-1 vision notice applies to Eli Lilly and Novo Nordisk alike, and Lilly's stock advanced that day. Definium's story is about funding, since roughly USD 1.05 billion can support DT120 through a filing in the first half of 2027. The upcoming FDA discussions at NovoCure and Definium are the dates to monitor.